2023
MGMT promoter methylation in 1p19q-intact gliomas
Kinslow C, Siegelin M, Iwamoto F, Gallitto M, Neugut A, Yu J, Cheng S, Wang T. MGMT promoter methylation in 1p19q-intact gliomas. Journal Of Neuro-Oncology 2023, 166: 73-78. PMID: 38114801, DOI: 10.1007/s11060-023-04515-z.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseMGMT promoter methylationOverall survivalIDH-wildtypeMGMT statusAdjuvant temozolomideAnaplastic gliomasPromoter methylationAssociated with poor survivalAssociation of MGMTClinical efficacy of temozolomideIDH-mutant astrocytomasCox proportional hazards regression modelsIDH-wildtype gliomasKaplan-Meier methodWell-powered prospective studiesMGMT promoter statusEfficacy of temozolomideProportional hazards regression modelsInternational randomized phaseStandard-of-careHazards regression modelsCATNON trialAnaplastic astrocytomaCancer Database
2012
Status Quo—Standard-of-Care Medical and Radiation Therapy for Glioblastoma
Becker K, Yu J. Status Quo—Standard-of-Care Medical and Radiation Therapy for Glioblastoma. The Cancer Journal 2012, 18: 12-19. PMID: 22290252, DOI: 10.1097/ppo.0b013e318244d7eb.Peer-Reviewed Original ResearchConceptsRadiation therapyStandard treatmentMonths of diagnosisCases of glioblastomaDevelopment of temozolomideAdjuvant radiationAdjuvant temozolomideAggressive tumorsImproved survivalTreatment courseChemotherapy agentsSurgical interventionChemotherapeutic agentsCancer morbidityTemozolomideGlioblastomaMonthsSurvivalTherapyTreatmentChemoradiationCytoreductionStuppChemotherapyBiopsy